ReviewDiscover nano2026
Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge. Conventional therapies are often limited by poor tumor selectivity, systemic toxicity, multidrug resistance, and suboptimal pharmacokinetics. Nanotechnology offers a transformative approach in oncology. It enables targeted drug delivery, controlled or stimuli-responsive release, and multifunctional platforms that combine therapy and diagnostics. Nanoparticles enhance drug solubility, prolong circulation, and improve intracellular uptake. These advances are achieved through passive enhanced permeability and retention (EPR) and active targeting mechanisms. Despite robust preclinical success, clinical translation remains inconsistent. Factors such as pronounced inter- and intratumoral EPR variability, long-term toxicity or biodistribution concerns, immune recognition, and stringent regulatory or manufacturing hurdles contribute to high attrition rates. Approved nanomedicines, such as liposomal doxorubicin (Doxil
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.